ENVX Form 4 — 500,000 Warrants Donated; Trustee Keeps 1.91M
Rhea-AI Filing Summary
Enovix insider transaction: The Form 4 reports that 500,000 publicly-traded warrants were transferred as a bona fide gift from the Rodgers Massey Revocable Living Trust, for which Thurman J. Rodgers is trustee and retains voting and dispositive power, to a donor advised fund. The Warrants were originally distributed by the issuer on July 21, 2025 at no cost and each Warrant is exercisable for one share of common stock at an $8.75 exercise price. Following the reported gift, the Reporting Person beneficially owns 1,914,466 warrants indirectly through the Trust. The Warrants expire on October 1, 2026, subject to early-acceleration conditions in the Warrant Agreement.
Positive
- Warrants were distributed by the issuer at no cost on July 21, 2025, indicating issuance terms that did not require cash payment from initial recipients
- Beneficial ownership disclosure provided, clarifying the Reporting Person's indirect holdings of 1,914,466 warrants through the Trust
Negative
- 500,000 warrants were removed from the Trusts holdings via a gift to a donor advised fund, reducing that entitys potential future exercise-related capital inflow
- Warrants are exercisable into common stock at $8.75, which, if exercised, would dilute existing shareholders prior to the October 1, 2026 expiration
Insights
TL;DR: A trustee transferred 500,000 warrants to a donor advised fund while retaining control over remaining warrants, raising governance and insider-ownership notes.
The filing documents a non-sale, charitable gift of 500,000 warrants originally distributed by Enovix. The Reporting Person serves as trustee and retains voting and dispositive power over the remaining 1,914,466 warrants held by the Trust, which is relevant for assessing insider influence and potential future actions involving these derivative securities. The gift itself was executed without cash consideration, consistent with a bona fide charitable transfer and not a market disposal.
TL;DR: 500,000 warrants moved to a donor advised fund; warrants exercisable at $8.75 could convert to common shares before Oct 1, 2026.
The warrants underlying this Form 4 carry an $8.75 exercise price and each converts to one share of common stock. The instrument's expiration is October 1, 2026, subject to acceleration terms. From an investor standpoint, the transfer is a non-cash disposition that reduces the Trusts direct economic ownership of those 500,000 warrants while leaving control over the Trust-held balance intact. The transaction does not disclose any cash proceeds and appears structured as a gift.